NY-ICAP
ICAP plc (IAP.L), a leading markets operator and provider of post trade risk mitigation and information services, announces today that its UK subsidiary, ICAP Global Derivatives Limited (IGDL ), has officially launched having received temporary Swap Execution Facility (SEF) approval from the US Commodity Futures Trading Commission (CFTC). IGDL is the first global SEF and Multilateral Trading Facility (MTF), regulated by both the CFTC and the UK Financial Conduct Authority (FCA).
Laurent Paulhac, CEO of the ICAP SEF, said: “The launch of IGDL is an important initiative for our clients and our markets, mitigating the risk of liquidity fragmentation. With this dually regulated entity, market participants from all key jurisdictions can participate in the same global liquidity pool for our G3 rates products. In conjunction with this launch, we are rolling out our next generation voice Request for Quote (RFQ) protocol, called vRFQ 2.0, delivering voice execution services to our clients that are specifically designed to be compliant with UK and US regulations. vRFQ 2.0 is powered by technology innovation enabling our voice execution services to work seamlessly with i-Swap, our interest rate swap (IRS) electronic execution platform.”
IGDL allows ICAP to bridge the CFTC’s SEF rules with financial services regulation of the United Kingdom and European Economic Area (EEA), as a UK incorporated entity authorised and regulated by the FCA as well as registered as a SEF with the CFTC. The CFTC registration is in addition to IGDL’s UK regulatory permissions, which include the ability to operate a MTF, allowing the Group to take advantage of the MiFID passport regime for EEA liquidity. IGDL is also authorised to provide direct access to customers in the EEA and Canada (Ontario).
Peter Best, COO of the ICAP SEF, added: “With mandatory swaps trading now a requirement for many market participants across multiple asset classes, ICAP is committed to offering its customers market-leading execution solutions that manage their swap risk in a fully compliant manner. IGDL is the result of ICAP’s commercial, legal, regulatory, technology, and operational teams together focusing on delivering an unparalleled trading experience and multi-jurisdiction-compliant platform in response to client needs and expectations. We have consulted heavily with our major clients in the process and look forward to continue to be a trusted partner for all market participants now and in the years ahead as the marketplace adapts to a regulated trading environment, and we want to thank our customers sincerely for their support and confidence during this initial phase of the process.”
By registering to be a SEF with the CFTC, IGDL can provide direct access to market participants in both the US and EEA in a manner which satisfies SEF transaction level requirements and EEA regulatory rules via its electronic order books and US and London based voice swap execution specialists. IGDL, available to all market participants, integrates i-Swap, ICAP’s award-winning electronic interest rate platform, with vRFQ 2.0, allowing for the broadest and most efficient facilitation of liquidity.
IGDL will initially focus on G3 Rates, including USD, EUR and GBP - IRS, OIS, FRAs, IROs, Swaptions, Inflation and Exotic Swaps and Options. All other products and instruments will continue to be serviced on ICAP's existing US SEF, ICAP SEF (US) LLC. ICAP intends to migrate more products to IGDL and will seek additional permissions with relevant regulators to operate the IGDL SEF in more jurisdictions, such as countries in the Asia-Pacific region.
About IGDL
ICAP Global Derivatives Limited (IGDL), a subsidiary of ICAP plc, is ICAP’s UK-based MTF and SEF. The company is authorised and regulated by the UK Financial Conduct Authority (FCA) as well as registered as a SEF with the CFTC. The dual registration includes permission to operate a multi-lateral trading facility (MTF). IGDL allows reconciliation with the CFTC’s SEF rules with financial services regulation of the United Kingdom and European Economic Area. For more information, please go to www.icap.com/sef .
About the ICAP SEF US
ICAP SEF (US) LLC, a subsidiary of ICAP plc, operates markets for interest rate swaps (IRS), credit default swaps (CDS), equity derivatives, commodities and NDFs (non-deliverable forwards). The ICAP SEF offers a venue for trading in cleared and uncleared swaps and operates central limit order books (CLOB) and request for quote (RFQ) systems, as well as offering block trade capabilities, electronic crossing and execution via brokers. The ICAP SEF is headquartered in Jersey City, New Jersey. For more information, please go to www.icap.com/sef .
About i-Swap
i-Swap is ICAP's award-winning electronic trading platform for OTC interest rate derivatives, offering continuous streaming support across Euro and USD Interest Rate Swaps. i-Swap's automated matching model and implied strategy trading functionality allows ICAP to enhance its electronic liquidity through improving prices by linking liquidity in underlying swaps to liquidity in strategy orders such as spreads, butterflies, and spread-overs.
About ICAP
ICAP is a leading markets operator and provider of post trade risk mitigation and information services. Group companies provide services that match buyers and sellers in the wholesale markets in interest rates, credit, commodities, FX, emerging markets and equity derivatives through voice and electronic networks. Through our post trade risk and information services we help our customers manage and mitigate risks in their portfolios. For more information, please go to www.icap.com .
Contact:
ICAP plc
Serra Balls, +44 (0) 20 7050 7103
ICAP Group Head of
Communications
or
Guy Taylor, +1 212 341 9759
ICAP
Communications US
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum